Search Result

Results for "

HLA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CD74 (2) Amino Acid Derivatives (2) Antibiotic (7) Apoptosis (3) Bacterial (8) Biochemical Assay Reagents (1) C-type Lectin-like Receptors (CTLRs) (1) Calcium Channel (1) Cathepsin (1) CD28 (1) CD3 (1) CD47 (1) CMV (2) Complement System (1) DNA/RNA Synthesis (1) EBV (7) EGFR (2) HCV (1) HIV (2) HPV (3) IFNAR (3) Influenza Virus (4) Insulin Receptor (1) Interleukin Related (3) Isotope-Labeled Compounds (1) JNK (1) LAG-3 (2) MAP4K (1) MHC (5) Parasite (4) Reactive Oxygen Species (ROS) (2) Reference Standards (2) Ser/Thr Kinase (1) Small Interfering RNA (siRNA) (22) STING (1) TNF Receptor (4) Toll-like Receptor (TLR) (2) Transmembrane Glycoprotein (3) Tyrosinase (3)
By Research Areas:	Cancer (42) Infection (18) Inflammation/Immunology (24) Metabolic Disease (2) Neurological Disease (1)
Oligonucleotides:	CpG ODNs (4) Human Pre-designed siRNA Sets (22) siRNAs (22)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

227

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

HLA-A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-A Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DMB Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DMB Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DMB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-G Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-G Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-G gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-F Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-F Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-F gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-C Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-C Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DOA Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DOA Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DOA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DMA Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DMA Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DMA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-E Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-E Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DOB Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DOB Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DOB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DRA Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DRA Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DRA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-B Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DQB2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DQB2 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DQB3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DQB3 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQB3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DQA2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DQA2 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DPA1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DPA1 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DPA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DPB1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DPB1 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DPB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DQB1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DQB1 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DRB3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DRB3 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DRB3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DRB5 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DRB5 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DRB5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DQA1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DQA1 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DRB4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DRB4 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DRB4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DRB1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DRB1 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DRB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

H052	Bacterial Calcium Channel	Infection
H052 is a selective Staphylococcus aureus α-hemolysin (Hla) inhibitor. H052 binds to Hla monomers, disrupts the interaction with host cell membranes to block pore formation, inhibiting calcium ion influx, cytotoxicity, and inflammatory responses. H052 exhibits potency (EC₅₀=30 nM in U937 cells) against Hla-induced calcium influx. H052 is promising for research of lung infections caused by S. aureus .

*Anti-HLA-A2 (Hu8F4)*	MHC	Cancer
Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting *HLA-A2. Anti-HLA*-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

*Influenza A NP (383-391) (HLA-B27)*	Transmembrane Glycoprotein Influenza Virus	Cancer
Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .

*Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)*	MHC Apoptosis Reactive Oxygen Species (ROS)	Infection Cancer
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/human MHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma .

KVS0001	Ser/Thr Kinase	Cancer
KVS0001 is a selective SMG1 inhibitor. KVS0001 elevates the expression of transcripts and proteins resulting from truncating mutations. KVS0001 increased the presentation of immune-targetable HLA class I-associated peptides from nonsense-mediated decay (NMD)-downregulated proteins on the surface of cancer cells. KVS0001 exerts anti-tumor properties and can be studied in research for NMD-related diseases, including cancer and inherited diseases .

Human MOG-specifying DNA	Others	Neurological Disease Inflammation/Immunology
Human MOG-specifying DNA is located at chromosome 6 within the human leukocyte antigen (HLA) gene locus. Human MOG-specifying DNA is exclusively expressed in the central nervous system (CNS) on the surface of myelin sheaths and oligodendrocytes (ODCs) processes, with unique methylation patterns in ODCs. Human MOG-specifying DNA can be used for inflammatory demyelinating diseases such as multiple sclerosis (MS) research .

Tosatoxumab KBSA301; AR-301	Antibiotic Bacterial	Infection
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .

Schisandrone	CD74	Cancer
Schisandrone, a 4-aryltetralone lignan, is isolated from the dried fruits of Schisandra sphenanthera . Schisandrone is an alpha-hemolysin (Hla) inhibitor that downregulates the transcript levels of hla, agrA and RNAIII. Hla is an integral virulence determinant in Staphylococcus aureus that determines pathogenicity. Schisandrone is a potent inhibitor against MRSA pneumonia .

YLLEMLWRL	EBV	Cancer
YLLEMLWRL is an HLA-A2-restricted T cell epitope sequence corresponding to codon 125-133. Among them, YLLEMLWRL sequence is the main mutation site of HLA-A2-restricted CTL epitope sequence .

BCMA72-80	TNF Receptor	Cancer
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .

CEF20	CMV	Infection
CEF20 is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).

CEF20 TFA	CMV	Infection
CEF20 TFA is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro*. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .

Polzastobart JTX 8064	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .

HIV p17 Gag (77-85)	HIV	Infection
HIV p17 Gag (77-85) is an HLA-A*0201(A2)-restricted CTL epitope, used in the research of anti-HIV .

CEF14, EBV Rta Protein (28-37)	EBV	Infection
CEF14, EBV Rta Protein (28-37) is the HLA A24-restricted epitope from Epstein-Barr Virus Rta protein (28-37).

EBV EBNA3B (416-424)	EBV	Inflammation/Immunology
EBV EBNA3B (416-424) is an HLA-A11-restricted peptide antigen derived from EBV EBNA3B protein .

Influenza virus PA (46-54)	DNA/RNA Synthesis Influenza Virus	Others
Influenza virus PA (46-54) is a biological active peptide. (HLA-A*0201 restricted epitope from influenza virus RNA polymerase subunit, PA (46-54).)

EBV EBNA3A (379-387)	EBV	Infection Inflammation/Immunology
EBV EBNA3A (379-387) is an antigenic epitope that may elicit the latent-specific CD8 ⁺ T cell response in HLA-B*07:02 ⁺ individuals .

Epstein-barr virus BRLF1 (134-142)	EBV	Others
Epstein-barr virus BRLF1 (134-142) is a biological active peptide. (HLA-A11 restricted epitope from Epstein-Barr Virus BRLF1 (134-142).)

BMLF1 (280–288)	EBV	Others
BMLF1 (280–288) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus lytic protein BMLF1 (280-288).)

Insulin alpha-chain (1-13)	Insulin Receptor	Metabolic Disease
Insulin alpha-chain (1-13) is a human leucocyte antigen (HLA)-DR4-restricted epitope comprising the first 13 amino acids of the insulin A-chain .

LMP2A (426-434)	EBV	Others
LMP2A (426-434) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus latent membrane protein LMP2 (426-434).)

[Asp371]-Tyrosinase (369-377), human	Tyrosinase	Cancer
Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy .

Cat. No.	Product Name	Target	Research Area

HY-P1780A

CEF20 TFA	CMV	Infection
CEF20 TFA is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).

HY-P10662

HLA-B*0801-binding EBV peptide	Peptides	Infection Inflammation/Immunology
HLA-B0801-binding EBV peptide is an Epstein-Barr virus (EBV) epitope FLRGRAYGL. HLA-B0801-binding EBV peptide can bind to the HLA-B0801 molecule. HLA-B0801-binding EBV peptide can be presented to CD8+ T cells through HLA-B*0801 to activate a specific immune response .

HY-P10593

*Influenza A NP (383-391) (HLA-B27)*	Transmembrane Glycoprotein Influenza Virus	Cancer
Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .

HY-P2507

NY-ESO-1 (87-111)	Peptides	Cancer
NY-ESO-1 (87-111) is a pan-MHC class II-restricted peptide sequence. NY-ESO-1 (87-111) binds to multiple HLA-DR and HLA-DP4 molecules, and stimulates Th1-type and Th-2/Th0-type CD4 ⁺ T cells when presented in the context of HLA-DR and HLA-DP4 molecules .

HY-P5294

YLLEMLWRL	EBV	Cancer
YLLEMLWRL is an HLA-A2-restricted T cell epitope sequence corresponding to codon 125-133. Among them, YLLEMLWRL sequence is the main mutation site of HLA-A2-restricted CTL epitope sequence .

HY-P4667

VLHDDLLEA	Peptides	Metabolic Disease
VLHDDLLEA is a peptide that can be isolated from the MHC complex HLA-A0201 molecule. VLHDDLLEA can be recognized by HLA-A0201-restricted cytotoxic T cells (CTLs). VLHDDLLEA can be used for research on graft versus host disease (GvHD) .

HY-P1700

BCMA72-80	TNF Receptor	Cancer
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .

HY-P10339

SMCY peptide	Peptides	Inflammation/Immunology
SMCY peptide inhibits the binding of iodinated standard peptide to *HLA-B7* with an IC₅₀ of 34 nM. As an epitope of the H-Y antigen, SMCY peptide can be presented by the HLA-B7 molecule and recognized by specific T cells, leading to transplant rejection .

HY-P1780

CEF20	CMV	Infection
CEF20 is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).

HY-P4628

TPNQRQNVC LRH-1 peptide	Peptides	Inflammation/Immunology
TPNQRQNVC is a nonapeptide and is the epitope of HLA-B0702. TPNQRQNVC induces a CD8+ T cell immune response .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro*. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .

HY-P5476

Influenza virus NP (44-52)	Peptides	Others
Influenza virus NP (44-52) is a biological active peptide. (HLA-A*01 restricted epitope from influenza virus nucleoprotein (44-52).)

HY-P5477

Influenza virus NP (266-274)	Peptides	Others
Influenza virus NP (266-274) is a biological active peptide. (HLA-A*03 restricted epitope from influenza virus nucleoprotein (265-274).)

HY-P1842

MAGE-A3 (195-203)	Peptides	Cancer
MAGE-A3 (195-203) is a human leukocyte antigen (HLA) -A24 molecules epitope encoded by melanoma antigen gene (MAGE) .

HY-P1757

HIV p17 Gag (77-85)	HIV	Infection
HIV p17 Gag (77-85) is an HLA-A*0201(A2)-restricted CTL epitope, used in the research of anti-HIV .

HY-P1890

CEF14, EBV Rta Protein (28-37)	EBV	Infection
CEF14, EBV Rta Protein (28-37) is the HLA A24-restricted epitope from Epstein-Barr Virus Rta protein (28-37).

HY-P10664

EBV EBNA3B (416-424)	EBV	Inflammation/Immunology
EBV EBNA3B (416-424) is an HLA-A11-restricted peptide antigen derived from EBV EBNA3B protein .

HY-106187

MART-1 (27-35) (human)	Peptides	Inflammation/Immunology
MART-1 (27-35) (human) is an immunogenic epitope recognized by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TIL) .

HY-P5478

Influenza virus PA (46-54)	DNA/RNA Synthesis Influenza Virus	Others
Influenza virus PA (46-54) is a biological active peptide. (HLA-A*0201 restricted epitope from influenza virus RNA polymerase subunit, PA (46-54).)

HY-P10663

EBV EBNA3A (379-387)	EBV	Infection Inflammation/Immunology
EBV EBNA3A (379-387) is an antigenic epitope that may elicit the latent-specific CD8 ⁺ T cell response in HLA-B*07:02 ⁺ individuals .

HY-P3644

EEKLIVVAF	Peptides	Cancer
EEKLIVVAF is a pepitide, can be recognized on HLA-B44 by the anti-melanoma cytolytic T-cell (CTL) clone LB33- CTL-159/5 .

HY-P5482

Epstein-barr virus BRLF1 (134-142)	EBV	Others
Epstein-barr virus BRLF1 (134-142) is a biological active peptide. (HLA-A11 restricted epitope from Epstein-Barr Virus BRLF1 (134-142).)

HY-P5475

BMLF1 (280–288)	EBV	Others
BMLF1 (280–288) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus lytic protein BMLF1 (280-288).)

HY-P1901

Insulin alpha-chain (1-13)	Insulin Receptor	Metabolic Disease
Insulin alpha-chain (1-13) is a human leucocyte antigen (HLA)-DR4-restricted epitope comprising the first 13 amino acids of the insulin A-chain .

HY-P5470

LMP2A (426-434)	EBV	Others
LMP2A (426-434) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus latent membrane protein LMP2 (426-434).)

HY-P1919

[Asp371]-Tyrosinase (369-377), human	Tyrosinase	Cancer
Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy .

HY-P3813

Tyrosinase (206-214), human	Tyrosinase	Inflammation/Immunology Cancer
Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL) .

HY-P1857

CEF7, Influenza Virus NP (380-388)	Influenza Virus	Infection
CEF7, Influenza Virus NP (380-388) is a HLA-B ^*08 restricted influenza virus nucleoprotein epitope. Influenza virus NP functions as a key adapter molecule between virus and host cell processes .

HY-P10264

MAGE-3 peptide MAGE-3(168-176), human	Peptides	Cancer
MAGE-3 peptide (MAGE-3 168-176, human) is a peptide encoded by human MAGE-3 gene, which is expressed in tumor cells, presented by HLA and recognized by cytolytic T lymphocytes (CTL) as tumor antigen .

HY-P0277

Carcinoembryonic antigen peptide 1 CEA peptide	Peptides	Cancer
Carcinoembryonic antigen peptide 1 (CEA peptide) is a carcinoembryonic antigen (CEA)-derived peptide. Carcinoembryonic antigen peptide 1 is a potential HLA-A*0201-restricted CTL epitope that can be used for the study of CTL-mediated epithelial-derived cancers .

HY-P3640

MAGE-3 Antigen (167-176) (human)	Peptides	Cancer
MAGE-3 Antigen (167-176) (human) is a polypeptide containing eight amino acids. MAGE-3 Antigen (167-176) (human) is a human leukocyte antigen HLA-B44 molecules epitope encoded by melanoma antigen gene (MAGE) .

HY-P3742

Tyrosinase (192-200), human mouse	Tyrosinase	Cancer
Tyrosinase (192-200), human mouse is a nonapeptide. Tyrosinase (192-200), human mouse can be recognized by cytolytic T cell (CTL) on the HLA-B44 molecule. Tyrosinase (192-200), human mouse can be used in research of melanoma associated cancers .

HY-P1778

HPV16 E7 (86-93)	HPV	Infection
HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas .

HY-P1835

CEF8, Influenza Virus NP (383-391)	Influenza Virus	Inflammation/Immunology
CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B ^*2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic T lymphocytes-mediated immunity .

HY-P1778A

HPV16 E7 (86-93) (TFA)	HPV	Infection
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas .

HY-P1914

NY-BR-1 p904 (A2)	Peptides	Cancer
NY-BR-1 p904 (A2) is an HLA-A2-restricted NY-BR-1 epitope. T-cell clone specific for NY-BR-1 p904 can recognize breast tumor cells expressing NY-BR-1 .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-P5425

Tetanus Toxin (830–844)	Peptides	Others
Tetanus Toxin (830–844) is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4+ T-cell epitope. This promiscuous CD4+ T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4+ T-cell responses in a large part of the human population)

HY-P3248

J5 peptide Myelin basic protein (85-99) antagonist	Biochemical Assay Reagents	Inflammation/Immunology
J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP_85-99 to *HLA-DR2*. J5 peptide alleviates PLP_139-151/MBP_85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .

HY-P5425A

Tetanus Toxin (830–844) TFA	Transmembrane Glycoprotein	Cancer
Tetanus Toxin (830–844) TFA is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4 ⁺ T-cell epitope. This promiscuous CD4 ⁺ T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4 ⁺ T-cell responses in a large part of the human population) .

HY-P1826

CLIP (86-100)	CD74	Inflammation/Immunology Cancer
CLIP (86-100) is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP). CLIP is a small self-peptide and cleavage product of the invariant chain that resides in the HLA-II antigen binding groove and is believed to play a critical role in the assembly and transport of MHC class II alphabetaIi complexes through its interaction with the class II peptide-binding site .

HY-P1826A

CLIP (86-100) (TFA)	Peptides	Inflammation/Immunology Cancer
CLIP (86-100) TFA is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP). CLIP is a small self-peptide and cleavage product of the invariant chain that resides in the HLA-II antigen binding groove and is believed to play a critical role in the assembly and transport of MHC class II alphabetaIi complexes through its interaction with the class II peptide-binding site .

HY-P5898

Z-Val-Val-Nle-diazomethylketone Z-Val-Val-Nle-CHN2	Cathepsin MHC	Inflammation/Immunology
Z-Val-Val-Nle-diazomethylketone is a cathepsin S (CATS) inhibitor. Z-Val-Val-Nle-diazomethylketone significantly inhibits the IFNg-induced upregulation of the MHCII molecules HLA-DR and Ii-p33/35 with an increase of Ii-p10 protein level. Z-Val-Val-Nle-diazomethylketone can be used for dermatological diseases like psoriasis, atopic dermatitis and actinic keratosis research .

HY-P4032

HCV Peptide (35-44)	HCV	Inflammation/Immunology
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .

HY-P2524

MAGE-3 (271-279)	Peptides	Cancer
MAGE-3 (271-279) is a 271-279 residue peptide derived from melanoma antigens encoded by MAGE-3. MAGE-3 is a cytolytic T lymphocyte (CTL)-defined MAGE-3 protein associated with the human leukocyte antigen (HLA)-A2 molecule. MAGE-3 is overexpressed in different human tumor types, including malignant melanoma, but not by normal tissues except for testis and placenta .

HY-P5503

Pol (476-484), HIV-1 RT Epitope	HIV	Others
Pol (476-484), HIV-1 RT Epitope is a biological active peptide. (This is a reverse transcriptase (RT) epitope (Pol residues 476-484). Within HIV-1 RT the peptide appears to be the dominant HLA A*0201-restricted epitope. Was used to investigate possible mechanisms behind HIV-1 escape from CTL. IV9 is the actual epitope processed and presented in HIV-1-infected cell lines.)

HY-P10493

NY-ESO-1 (157-165) peptide	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-P10493A

NY-ESO-1 (157-165) peptide TFA	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-P10835

LAG-3 cyclic peptide inhibitor C25	LAG-3	Cancer
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a K_d value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with *HLA-DR* (MHC-II) and activate CD8 ⁺ T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .

HY-P10994

Eps8 peptide 327 Eps8(327-335)	EGFR IFNAR Interleukin Related TNF Receptor Complement System Apoptosis	Inflammation/Immunology Cancer
Eps8 peptide 327 is an HLA-A2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis* and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models .

Cat. No.	Product Name	Target	Research Area

HY-P990189

*Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)*	MHC Apoptosis Reactive Oxygen Species (ROS)	Infection Cancer
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/human MHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma .

HY-P99551

Tosatoxumab KBSA301; AR-301	Antibiotic Bacterial	Infection
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .

HY-P990061

Polzastobart JTX 8064	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-P991247

*Anti-HLA-A2 (Hu8F4)*	MHC	Cancer
Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting *HLA-A2. Anti-HLA*-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991248

TTX-080	Inhibitory Antibodies	Cancer
TTX-080 is a humanized monoclonal antagonistic antibody targeting human leukocyte antigen G (HLA-G). TTX-080 exerts anti-tumor activity by relieving HLA-G-mediated immune suppression. TTX-080 is promising for research of solid tumors such as metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (mHNSCC) .

HY-P991230

MK-4830	Inhibitory Antibodies	Cancer
MK-4830 is a fully humanized monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to ILT4 and blocks its interaction with HLA-G and other ligands. MK-4830 inhibits tumor growth in humanized mouse cancer models .

HY-P990714

Obertamig	CD3	Inflammation/Immunology
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .

HY-P990606

IMMU-114	Inhibitory Antibodies	Inflammation/Immunology
IMMU-114 is a CHO expressed humanized antibody that targets *HLA-DR*. IMMU-114 is composed of huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.1 kDa. The isotype control for IMMU-114 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P991366

IBI-397 AL008	CD47	Cancer
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100*-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

HY-P991610

S-095029 Sym025	C-type Lectin-like Receptors (CTLRs)	Cancer
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .

HY-P990832

Anti-MHC Class I Antibody (W6/32)	MHC	Inflammation/Immunology
Anti-MHC Class I Antibody (W6/32) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human MHC Class I. Anti-MHC Class I Antibody (W6/32) reacts with the human major histocompatibility complex (MHC) class I, HLA-A, B, and C. Anti-MHC Class I Antibody (W6/32) increases adherence of monocytes to human endothelial cells. Anti-MHC Class I Antibody (W6/32) can be used for the research of immunology .

HY-P991590

1D09C3	MHC Apoptosis JNK Reactive Oxygen Species (ROS)	Cancer
1D09C3 is a fully human anti-HLA-DR monoclonal antibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL) .

Species:	Human (218) Rhesus Macaque (1) Mouse (5) Cynomolgus (3) Staphylococcus aureus (1)
Tag:	His (225) SUMO (2) Avi (207) Myc (1) GST (1) Fc (1)
Source:	HEK293 (213) CHO (1) Sf9 insect cells (1) P. pastoris (1) E. coli (11)

Cat. No.	Compare	Product Name	Species	Source

HY-P71699

	HLA-B Protein, Human (His) HLA-B protein; MHC class I antigen; HLA-B	Human	E. coli
	HLA-B Protein, a member of the major histocompatibility complex (MHC) class I family, is acknowledged. HLA-B Protein, Human (His) is the recombinant human-derived HLA-B protein, expressed by E. coli , with N-6*His labeled tag.

HY-P71696

	HLA-DPB1 Protein, Human (His) HLA class II histocompatibility antigen; HLA class II histocompatibility antigen; DP beta 1 chain; HLA class II histocompatibility antigen; HLA-DP1B; HLA-DPB	Human	E. coli

HY-P71700

	HLA-C Protein, Human (His) HLA class I histocompatibility antigen, C alpha chain; HLA-C protein; MHC class I antigen; HLA-Cw	Human	E. coli

HY-P72288

	HLA-A Protein, Human (His) HLA class I histocompatibility antigen,A-1 alpha chain	Human	E. coli
	HLA-A protein is an antigen-presenting MHCI molecule that is critical for mediating reproductive and antiviral immunity. It partners with B2M to provide self- and viral peptides as ligands that inhibit and activate KIR on NK cells. HLA-A Protein, Human (His) is the recombinant human-derived HLA-A protein, expressed by E. coli , with N-6*His labeled tag.

HY-P71463

	HLA-DMA Protein, Human (His) HLA-DMA protein	Human	E. coli
	HLA-DMA proteins are key members of the MHC class II family and are essential for antigen presentation and immune response regulation. In this family, HLA-DMA is actively involved in the loading and exchange of peptides within the MHC class II antigen-binding groove. HLA-DMA Protein, Human (His) is the recombinant human-derived HLA-DMA protein, expressed by E. coli , with N-His labeled tag.

HY-P72227

	HLA-G Protein, Human (His-SUMO) B2 microglobulin; DADB-15K14.8; HLA 6.0; HLA class I histocompatibility antigen alpha chain G; HLA class I histocompatibility antigen; alpha chain G; HLA class I molecule; HLA G; HLA G antigen; HLA G histocompatibility antigen class I G; HLA G3; HLA-G; HLA-G histocompatibility antigen; class I; HLA60; HLAG; HLAG_HUMAN; Major histocompatibility complex class I G; MHC class I antigen; MHC class I antigen G; MHC G; T-cell A locus; TCA	Human	E. coli
	HLA-G is a nonclassical major histocompatibility class Ib molecule that is critical for immune regulation at the maternal-fetal interface. It cooperates with B2M to form a complex that selectively binds self-peptides to promote maternal-fetal tolerance by interacting with KIR2DL4, LILRB1, and LILRB2 receptors. HLA-G Protein, Human (His-SUMO) is the recombinant human-derived HLA-G protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.

HY-P705379

	HLA-DRA101:01&HLA-DRB104:01 Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-DRA10101 & HLA-DRB10401	Human	HEK293

HY-P705460

	HLA-G Protein, Human (sf9, His) HLA class I histocompatibility antigen, alpha chain G; HLA G antigen; MHC class I antigen G; HLA-6.0; HLAG	Human	Sf9 insect cells

HY-P705385

	HLA-DRA101:01&HLA-DRB11501&MBP(ENPVVHFFKNIVTPR) Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-DRA10101 & HLA-DRB11501 & MBP(ENPVVHFFKNIVTPR)	Human	HEK293

HY-P701001

	HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC-G; sHLA-G	Cynomolgus	HEK293

HY-P704845

	HLA-G Protein, Human (182a.a, His) HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G	Human	E. coli

HY-P705380

	HLA-DRA101:01&HLA-DRB104:01&GAD65(NFFRMVISNPAAT) Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-DRA10101 & HLA-DRB10401 & GAD65 (NFFRMVISNPAAT)	Human	HEK293

HY-P705381

	HLA-DRA101:01&HLA-DRB104:01&Influenza HA(PKYVKQNTLKLAT) Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-DRA10101 & HLA-DRB10401 & Influenza HA (PKYVKQNTLKLAT)	Human	HEK293

HY-P78455

	HLA-G Protein, Human (C66S, His-Avi) HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G	Human	E. coli
	HLA-G is a nonclassical major histocompatibility class Ib molecule that is critical for immune regulation at the maternal-fetal interface. It cooperates with B2M to form a complex that selectively binds self-peptides to promote maternal-fetal tolerance by interacting with KIR2DL4, LILRB1, and LILRB2 receptors. HLA-G Protein, Human (C66S, His-Avi) is the recombinant human-derived HLA-G protein, expressed by E. coli , with C-Avi, C-His labeled tag and C66S, , , , mutation.

HY-P705382

	HLA-DRA101:01&DRB111:01 Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-DRA10101 & HLA-DRB11101	Human	HEK293

HY-P71697

	HLA-DPA1 Protein, Human (His) HLA-DPA1; HLA-DP1A; HLASBHLA class II histocompatibility antigen; DP alpha 1 chain; HLA-SB alpha chain; MHC class II DP3-alpha; MHC class II DPA1	Human	E. coli
	The HLA-DPA1 protein is critical in the immune system, binding antigens in the endocytic pathway of APCs and presenting them to the cell surface for recognition by CD4 T cells. The peptide binding cleft can accommodate peptides of 10-30 residues, mainly resulting from protein degradation. HLA-DPA1 Protein, Human (His) is the recombinant human-derived HLA-DPA1 protein, expressed by E. coli , with N-His labeled tag.

HY-P77687

	HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein, Cynomolgus (HEK293, His-Avi) HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G	Cynomolgus	HEK293

HY-P77688

	HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein, Human (HEK293, His-Avi) HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G	Human	HEK293

HY-P77689

	HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G	Human	HEK293

HY-P77690

	HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein, Human (HEK293, His-Avi) HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G	Human	HEK293

HY-P77691

	HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein, Human (Biotinylated, HEK293, His-Avi) HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G	Human	HEK293

HY-P77692

	HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein, Rhesus Macaque (HEK293, His-Avi) HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G	Rhesus Macaque	HEK293

HY-P700735

	HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein, Cynomolgus (HEK293, His-Avi) HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G	Cynomolgus	HEK293

HY-P705383

	HLA-DRA101:01&DRB111:01&CLIP (PVSKMRMATPLLMQA) Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-DRA10101 & HLA-DRB11101 & CLIP (PVSKMRMATPLLMQA)	Human	HEK293

HY-P705384

	HLA-DRA101:01&DRB111:01&Influenza HA (PKYVKQNTLKLAT) Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-DRA10101 & HLA-DRB11101 & Influenza HA (PKYVKQNTLKLAT)	Human	HEK293

HY-P705303

	HLA-A01:01&B2M Monomer Protein, Human (Biotinylated, CHO, His-Avi) HLA-A01:01 B2M	Human	CHO

HY-P705375

	HLA-C03:03&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-C0303&B2M	Human	HEK293

HY-P72377

	HLA-A02:01&B2M&GP100(IMDQVPFSV) Monomer Protein, Human (Biotinylated, HEK293, Avi-His) Beta-2-microglobulin; B2M; HLA* class I histocompatibility antigen, A alpha chain; HLA-A	Human	HEK293

HY-P71505

	HLA-DRB1 Protein, Human (Myc, His-SUMO) HLA class II histocompatibility antigen, DRB1 beta chain; Human leukocyte antigen DRB1	Human	E. coli
	HLA-DRB1 protein, as the beta chain of MHCII, guides T cell recognition, orchestrates immune responses against pathogens and tumors, and adapts its antigen presentation in the tumor microenvironment, ensuring a diverse role in immune responses and tolerance mechanisms, notably influenced by specific alleles like DRB101:01. HLA-DRB1 Protein, Human (Myc, His-SUMO) is the recombinant human-derived HLA-DRB1 protein, expressed by E. coli* , with N-His, C-Myc, N-SUMO labeled tag.

HY-P705346

	HLA-A02:06&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-A0206 & B2M	Human	HEK293

HY-P705347

	HLA-A03:01&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-A0301 & B2M	Human	HEK293

HY-P705351

	HLA-A11:01&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-A1101 & B2M	Human	HEK293

HY-P705359

	HLA-A24:02&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-A2402 & B2M	Human	HEK293

HY-P705365

	HLA-A26:01&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-A2601 & B2M	Human	HEK293

HY-P705366

	HLA-A33:03&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-A3303 & B2M	Human	HEK293

HY-P705368

	HLA-B07:02&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-B0702 & B2M	Human	HEK293

HY-P705370

	HLA-B08:01&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-B0801 & B2M	Human	HEK293

HY-P705371

	HLA-B15:01&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-B1501 & B2M	Human	HEK293

HY-P705372

	HLA-B15:02&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-B1502 & B2M	Human	HEK293

HY-P705373

	HLA-B27:05&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-B2705 & B2M	Human	HEK293

HY-P705374

	HLA-B40:01&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-B4001 & B2M	Human	HEK293

HY-P705376

	HLA-C03:04&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-C0304 & B2M	Human	HEK293

HY-P705378

	HLA-C08:01&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-C0801 & B2M	Human	HEK293

HY-P705386

	HLA-E01:03&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-E0103 & B2M	Human	HEK293

HY-P705377

	HLA-C07:02:01&B2M Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-C070201 & B2M	Human	HEK293

HY-P705311

	HLA-A02:01&B2M&Glypican 3(FVGEFFTDV) Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLA-A02:01&B2M&Glypican 3 (FVGEFFTDV)	Human	HEK293

HY-P77758

	HLA-E01:03&B2M&Peptide(VMAPRTLVL) Monomer Protein, Human (HEK293, His-Avi) HLAE; sHLA-E; HLAE; MHC class I antigen E; MHC HLA-E alpha-1; MHC HLA*-E alpha-2.1; MHC; QA1	Human	HEK293

HY-P77760

	HLA-E01:03&B2M&Peptide(VMAPRTLVL) Tetramer Protein, Human (HEK293, His-Avi) HLAE; sHLA-E; HLAE; MHC class I antigen E; MHC HLA-E alpha-1; MHC HLA*-E alpha-2.1; MHC; QA1	Human	HEK293

HY-P77759

	HLA-E01:03&B2M&Peptide(VMAPRTLVL) Monomer Protein, Human (Biotinylated, HEK293, His-Avi) HLAE; sHLA-E; HLAE; MHC class I antigen E; MHC HLA-E alpha-1; MHC HLA*-E alpha-2.1; MHC; QA1	Human	HEK293

HY-P77761

	HLA-E01:03&B2M&Peptide(VMAPRTLVL) Tetramer Protein, Human (Biotinylated, HEK293, His-Avi) HLAE; sHLA-E; HLAE; MHC class I antigen E; MHC HLA-E alpha-1; MHC HLA*-E alpha-2.1; MHC; QA1	Human	HEK293

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B1455S1

Clindamycin-13C,d3

Clindamycin- ¹³C,d₃ is the ¹³C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-B1455S

Clindamycin-d3 hydrochloride

Clindamycin-d₃ (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82867

	HLA-B Antibody (YA2612) HLA B; HLAB	WB, IHC-P	Human
	HLA-B Antibody (YA2612) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2612), targeting HLA B, with a predicted molecular weight of 40 kDa (observed band size: 40 kDa). HLA-B Antibody (YA2612) can be used for WB, IHC-P experiment in human background.

HY-P83339

	HLA-DR Antibody (YA3084) MLRW; HLA-DRA1; MHC class II antigen DRA; HLA class II histocompatibility antigen; DR alpha chain	WB, IHC-P, ICC/IF, FC	Human
	HLA-DR Antibody (YA3084) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3084), targeting HLA DR, with a predicted molecular weight of 29 kDa (observed band size: 29 kDa). HLA-DR Antibody (YA3084) can be used for WB, IHC-P, ICC/IF, FC experiment in human background.

HY-P83945

	HLA-DPB1 Antibody (YA3642) DPB1; HLA-DP; HLA-DPB; HLA-DP1B	IHC-P, FC, ELISA	Human, Rat
	HLA-DPB1 Antibody (YA3642) is a mouse-derived and non-conjugated IgG1 antibody, targeting to HLA-DPB1. It can be applicated for IHC-P, FC, ELISA assays, in the background of human, rat.

HY-P83480

	HLA G Antibody (YA3225) HLA G antigen; MHC class I antigen G; HLA-G; HLA60; HLAG	WB	Human
	HLA G Antibody (YA3225) is a non-conjugated IgG antibody, targeting HLA G, with a predicted molecular weight of 38 kDa (observed band size: 42 kDa). HLA G Antibody (YA3225) can be used for WB experiment in human background.

HY-P84246

	HLA-F Antibody (YA3943) HLAF; CDA12; HLA-5.4; HLA-CDA12	WB, FC, ELISA	Human, Mouse, Rat
	HLA-F Antibody (YA3943) is a mouse-derived and non-conjugated IgG2b antibody, targeting to HLA-F. It can be applicated for WB, FC, ELISA assays, in the background of human, mouse, rat.

HY-P83916

	HLA-DR Antibody (YA3613) MLRW; HLA-DRA1	WB, ICC/IF, FC, ELISA	Human
	HLA-DR Antibody (YA3613) is a mouse-derived and non-conjugated IgG2b antibody, targeting to HLA-DRA. It can be applicated for WB, ICC/IF, FC, ELISA assays, in the background of human.

HY-P83917

	HLA-DRB1 Antibody (YA3614) SS1; DRB1; HLA-DRB; HLA-DR1B	WB, IHC-P, FC, ELISA	Human
	HLA-DRB1 Antibody (YA3614) is a mouse-derived and non-conjugated IgG1 antibody, targeting to HLA-DRB1. It can be applicated for WB, IHC-P, FC, ELISA assays, in the background of human.

HY-P84161

	HLA-DPA1 Antibody (YA3858) DPA1; PLT1; HLADP; HLASB; DP(W3); DP(W4); HLA-DPA; HLA-DP1A; HLA-DPB1	WB, IHC-P, FC, ELISA	Human
	HLA-DPA1 Antibody (YA3858) is a mouse-derived and non-conjugated IgG2a antibody, targeting to HLA-DPA1. It can be applicated for WB, IHC-P, FC, ELISA assays, in the background of human.

HY-P84162

	HLA-DPA1 Antibody (YA3859) DPA1; PLT1; HLADP; HLASB; DP(W3); DP(W4); HLA-DPA; HLA-DP1A; HLA-DPB1	IHC-P, FC, ELISA	Human, Rat
	HLA-DPA1 Antibody (YA3859) is a mouse-derived and non-conjugated IgG2b antibody, targeting to HLA-DPA1. It can be applicated for IHC-P, FC, ELISA assays, in the background of human, rat.

HY-P86487

	HLA-DR Antibody (YA6179)	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	HLA-DR Antibody (YA6179) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-DRA. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.

HY-P81742

	HLA-DRB1 Antibody (YA1487) HLA-Drb1; DW2.2/DR2.2	WB, IHC-P, ICC/IF	Human
	HLA-DRB1 Antibody (YA1487) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1487), targeting HLA DRB1, with a predicted molecular weight of 30 kDa (observed band size: 30 kDa). HLA-DRB1 Antibody (YA1487) can be used for WB, IHC-P, ICC/IF experiment in human background.

HY-P83195

	HLA Class 1 A Antibody (YA2940) Aw-68; HLA class I histocompatibility antigen; A-28 alpha chain; MHC class I antigen A68; HLA-A; MHC class I antigen HLA* A heavy chain	WB, IHC-P, ICC/IF, IP, FC	Human
	HLA Class 1 A Antibody (YA2940) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2940), targeting HLA A, with a predicted molecular weight of 41 kDa (observed band size: 41 kDa). HLA Class 1 A Antibody (YA2940) can be used for WB, IHC-P, ICC/IF, IP, FC experiment in human background.

HY-P83098

	HLA-F Antibody (YA2843) HLAF	WB, IHC-P	Human
	HLA-F Antibody (YA2843) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2843), targeting HLA F, with a predicted molecular weight of 39 kDa (observed band size: 42 kDa). HLA-F Antibody (YA2843) can be used for WB, IHC-P experiment in human background.

HY-P82688

	HLA-DQA1 Antibody (YA2433) HLA-DQA1; CD; CELIAC1; DQ-A1; GSE; HLA-DQA; DQ alpha 1 chain; DC-1 alpha chain; DC-alpha; HLA-DCA; MHC class II DQA1	WB, IHC-P, IP	Human, Mouse, Rat
	HLA-DQA1 Antibody (YA2433) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2433), targeting HLA DQA1, with a predicted molecular weight of 28 kDa (observed band size: 28 kDa). HLA-DQA1 Antibody (YA2433) can be used for WB, IHC-P, IP experiment in human, mouse, rat background.

HY-P83274

	HLA-C Antibody (YA3019) MHC; HLAC; HLC-C; D6S204; PSORS1; HLA-JY3	WB, IP	Human, Mouse
	HLA-C Antibody (YA3019) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3019), targeting HLA C, with a predicted molecular weight of 41 kDa (observed band size: 41 kDa). HLA-C Antibody (YA3019) can be used for WB, IP experiment in human, mouse background.

HY-P84044

	HLA-C Antibody (YA3741) MHC; HLAC; HLC-C; D6S204; PSORS1; HLA-JY3	IHC-P, ICC/IF, FC, ELISA	Human
	HLA-C Antibody (YA3741) is a mouse-derived and non-conjugated IgG1 antibody, targeting to HLA-C. It can be applicated for IHC-P, ICC/IF, FC, ELISA assays, in the background of human.

HY-P83701

	HLA E Antibody (YA3437) HLA class I histocompatibility antigen E alpha chain antibody; EA1.2 antibody; EA2.1 antibody; HLA 6.2 antibody; HLA class I histocompatibility antigen alpha chain E antibody; HLA class I histocompatibility antigen E alpha chain precursor antibody; HLA class I histocompatibility antigen E alpha chain precursor antibody; HLA6.2 antibody; HLAE antibody; Lymphocyte antigen antibody; Major histocompatibility complex class I E antibody; MHC antibody; MHC class I antigen E antibody; MHC HLA E alpha 1 antibody; MHC HLA E alpha 2.1 antibody; QA1 antibody;	WB, IP, FC	Human
	HLA E Antibody is a non-conjugated and Mouse origined monoclonal antibody about 40 kDa, targeting to HLA E . It can be used for WB, IP, FC assays with tag free, in the background of Human.

HY-P83915

	HLA-B Antibody (YA3612) AS; HLAB; Bw-47; Bw-50; SPDA1; B-4901; B-5001; HLA-Cw;	WB, IHC-P, ICC/IF, FC, ELISA	Human
	HLA-B Antibody (YA3612) is a mouse-derived and non-conjugated IgG1 antibody, targeting to HLA-B. It can be applicated for WB, IHC-P, ICC/IF, FC, ELISA assays, in the background of human.

HY-P85015

	HLA-DR Antibody (YA4707) DASS-397D15.1 antibody; DR alpha chain antibody; DR alpha chain precursor antibody; DRA_HUMAN antibody; DRB1 antibody; DRB4 antibody; FLJ51114 antibody; Histocompatibility antigen HLA DR alpha antibody; Histocompatibility antigen HLA-DR alpha antibody; HLA class II histocompatibility antigen antibody; HLA class II histocompatibility antigen DR alpha chain antibody; HLA DR1B antibody; HLA DR3B antibody; HLA DRA antibody; HLA DRA1 antibody; HLA DRB1 antibody; HLA DRB3 antibody; HLA DRB4 antibody; HLA DRB5 antibody; HLA-DR histocompatibility type antibody; HLA-DRA antibody; HLADR4B antibody; HLADRA1 antibody; HLADRB antibody; Major histocompatibility complex class II DR alpha antibody; Major histocompatibility complex class II DR beta 1 antibody; Major histocompatibility complex class II DR beta 3 antibody; Major histocompatibility complex class II DR beta 4 antibody; Major histocompatibility complex class II DR beta 5 antibody; MGC117330 antibody; MHC cell surface glycoprotein antibody; MHC class II antigen DRA antibody; MHC II antibody; MLRW antibody; OTTHUMP00000029406 antibody; OTTHUMP00000029407 antibody; HLA-DRA nanobody;	ELISA	Human
	HLA-DR Antibody (YA4707) is a mouse-derived and non-conjugated monoclonal antibody, targeting to HLA-DRA. It can be applicated for ELISA assays, in the background of human.

HY-P81436

	HLA-DPA1 Antibody (YA1181) HLA DPA1; major histocompatibility complex; class II; DP alpha 1; PLT1; HLADP; HLASB; DP(W3); DP(W4); HLA-DP1A	IHC-P	Human
	HLA-DPA1 Antibody (YA1181) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1181), targeting HLA-DP. HLA-DPA1 Antibody (YA1181) can be used for IHC-P experiment in human background.

HY-P84941

	HLA Class 1 ABC Antibody (YA4638) Antigen Presenting Molecule antibody; Cw1701 antibody; D6S204 antibody; FLJ27082 antibody; HLA* A antibody; HLA B antibody; HLA C antibody; HLA class 1 A antibody; HLA class 1 B antibody; HLA class 1 C antibody; HLA JY3 antibody; HLAA antibody; HLAB antibody; HLAC antibody; HLC C antibody; Human Leucocyte Antigen C antibody; Major Histocompatibility Complex Class I A antibody; Major Histocompatibility Complex Class I B antibody; Major Histocompatibility Complex Class I C antibody; Major histocompatibility complex, class I, A + B + C antibody; MHC class I antigen A1 antibody; MHC Class I Antigen antibody; MHC class I antigen B7 antibody; MHC class I antigen Cw1 antibody; MHC class I HLA* A antibody; MHC class I HLA B antibody; MHC class I HLA C antibody; MHC HLA ABC antibody; PSORS1 antibody	ICC/IF, FC	Human
	HLA Class 1 ABC Antibody (YA4638) is a mouse-derived non-conjugated IgG antibody (Clone NO.: YA4638), targeting HLA Class 1 ABC. HLA Class 1 ABC Antibody (YA4638) can be used for ICC, FC experiment in human background.

HY-P83528

	HLA-DPB1 Antibody (YA3273) HLA class II histocompatibility antigen; DP beta 1 chain; HLADPB1; HLADP1B; HLADM	WB, IHC-P, ICC/IF, IP	Human
	HLA-DPB1 Antibody (YA3273) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3273), targeting HLA DPB1, with a predicted molecular weight of 29 kDa (observed band size: 29 kDa). HLA-DPB1 Antibody (YA3273) can be used for WB, IHC-P, ICC/IF, IP experiment in human background.

HY-P87245

	HLA-DRB4 Antibody (YA6933) DR 4 antibody	WB, IHC-P, FC	Human

HY-P86901

	HLA DMB Antibody (YA6594) class II antigen HLA-DM beta chain antibody; class II histocompatibility antigen antibody; Class II histocompatibility antigen M beta chain antibody; D6S221E antibody; DMB antibody; HLA class II histocompatibility antigen DM beta chain antibody; HLA-DM histocompatibility type, beta chain antibody; M beta chain antibody; Major histocompatibility complex class II DM beta antibody; MHC class II antigen DMB antibody; class II antigen HLA-DM beta chain antibody; class II histocompatibility antigen antibody; Class II histocompatibility antigen M beta chain antibody; D6S221E antibody; DMB antibody; HLA class II histocompatibility antigen DM beta chain antibody; HLA-DM histocompatibility type, beta chain antibody; M beta chain antibody; Major histocompatibility complex class II DM beta antibody; MHC class II antigen DMB antibody; MHC class II antigen HLA DM beta chain antibody; MHC class II HLA DMB antibody; OTTHUMP00000029257 antibody; Really interesting new gene 7 protein antibody; RING 7 antibody; RING7 antibody	WB, ICC/IF, IF-Tissue, FC	Human

HY-P83577

	MHC Class I Antibody (YA3322) Aw-68; HLA class I histocompatibility antigen; A-28 alpha chain; MHC class I antigen A68; HLA-A; MHC class I antigen HLA* A heavy chain	WB, IHC-P	Human
	MHC Class I Antibody (YA3322) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3322), targeting MHC Class I, with a predicted molecular weight of 41 kDa (observed band size: 41 kDa). MHC Class I Antibody (YA3322) can be used for WB, IHC-P experiment in human background.

HY-P85199

	HFE Antibody (YA4891) HFE; HLAH; Hereditary hemochromatosis protein; HLA-H	WB, ICC/IF, ELISA	Human
	HFE Antibody (YA4891) is a mouse-derived and non-conjugated monoclonal antibody, targeting to HFE. It can be applicated for WB, ICC/IF, ELISA assays, in the background of human.

HY-P81537

	CD74 Antibody (YA1282) CD74; DHLAG; HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33; CD74	IHC-P	Human
	CD74 Antibody (YA1282) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1282), targeting CD74. CD74 Antibody (YA1282) can be used for IHC-P experiment in human background.

HY-P85007

	CD74 Antibody (YA4699) HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33; CD antigen CD74; CD74 nanobody	ELISA, FC	Human
	CD74 Antibody (YA4699) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD74. It can be applicated for ELISA, FC assays, in the background of human.

HY-P85898

	CD74 Antibody (YA5590) CD 74 antibody; CD74 antibody; CD74 antigen; invariant polypeptide of major histocompatibility complex; class II antigen-associated; antibody; CD74 antigen antibody; CD74 molecule antibody; CD74 molecule; major histocompatibility complex; class II invariant chain antibody; CLIP antibody; DHLAG antibody; Gamma chain of class II antigens antibody; HG2A_HUMAN antibody; HLA class II histocompatibility antigen gamma chain antibody; HLA DR antigens associated invariant chain antibody; HLA DR gamma antibody; HLA-DR antigens-associated invariant chain antibody; HLA-DR-gamma antibody; HLADG antibody; HLADR antigens associated invariant chain antibody; Ia antigen associated invariant chain antibody; Ia antigen-associated invariant chain antibody; Ia associated invariant chain antibody; Ia gamma antibody; Ii antibody; Invariant polypeptide of major histocompatibility complex class II antigen associated antibody; la-gamma antibody; Major histocompatibility complex class II invariant chain antibody; MHC HLA DR gamma chain antibody; MHC HLA-DR gamma chain antibody; p33 antibody; p35 antibody; Protein 41 antibody;	IHC-P, WB, ICC/IF, ELISA	Human
	CD74 Antibody (YA5590) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CD74. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.

HY-P81719

	MICA Antibody (YA1464) PERB11.1; MICA; HLA class I antigen antibody; FLJ36918 antibody; FLJ60820 antibody; MGC111087 antibody; MGC21250 antibody; MHC class I chain related gene A protein antibody	WB, IP, FC	Human
	MICA Antibody (YA1464) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1464), targeting MICA. MICA Antibody (YA1464) can be used for WB, FC, IP experiment in human background.

HY-P83760

	MICA+MICB Antibody (YA3560) HLA class I antigen antibody; FLJ36918 antibody; FLJ60820 antibody; MGC111087 antibody; MGC21250 antibody; MHC class I chain related gene A protein antibody; MIC A antibody; micA antibody; MICA_HUMAN antibody; OTTHUMP00000029088 antibody; PERB11.1 antibody; Stress inducible class I homolog antibody; MHC class I chain related protein B antibody; MICB antibody MICB_HUMAN antibody PERB11.2 antibody Stress inducible class I homolog antibody	WB, IP, FC	Human
	MICA+MICB Antibody (YA3560) is a rabbit-derived non-conjugated IgG antibody, targeting MICA. MICA+MICB Antibody (YA3560) can be used for WB, FC, IP experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RS06196

HLA-A Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-A Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06200

HLA-DMB Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DMB Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DMB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06217

HLA-G Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-G Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-G gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06216

HLA-F Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-F Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-F gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06198

HLA-C Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-C Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06201

HLA-DOA Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DOA Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DOA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06199

HLA-DMA Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DMA Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DMA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06215

HLA-E Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-E Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06202

HLA-DOB Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DOB Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DOB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06210

HLA-DRA Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DRA Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DRA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06197

HLA-B Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-B Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06208

HLA-DQB2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DQB2 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06209

HLA-DQB3 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DQB3 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQB3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06206

HLA-DQA2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DQA2 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06203

HLA-DPA1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DPA1 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DPA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06204

HLA-DPB1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DPB1 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DPB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06207

HLA-DQB1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DQB1 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06212

HLA-DRB3 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DRB3 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DRB3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06214

HLA-DRB5 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DRB5 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DRB5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06205

HLA-DQA1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DQA1 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06213

HLA-DRB4 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DRB4 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DRB4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06211

HLA-DRB1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HLA-DRB1 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DRB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-150740A

ODN 21595 sodium		CpG ODNs
ODN 21595 sodium is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 sodium inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 sodium reduces the expression of CD86 and HLA-DR. ODN 21595 sodium has the potential for the research of systemic lupus erythematosus (SLE) .

HY-150740

ODN 21595		CpG ODNs
ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE) .

HY-150749

ODN D-SL03		CpG ODNs
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

HY-150749A

ODN D-SL03 sodium		CpG ODNs
ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks